[{"id":"9cbb0ca0-237d-473a-96a5-93ed04df6129","acronym":"","url":"https://clinicaltrials.gov/study/NCT03679754","created_at":"2021-07-05T17:17:13.012Z","updated_at":"2024-07-02T16:36:24.160Z","phase":"Phase 1","brief_title":"Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102","source_id_and_acronym":"NCT03679754","lead_sponsor":"Alaunos Therapeutics","biomarkers":" CD8 • IFNG • CD4","pipe":"","alterations":" ","tags":["CD8 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ad-RTS-hIL-12 • veledimex (INXN-1001)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 09/05/2018","start_date":" 09/05/2018","primary_txt":" Primary completion: 04/02/2019","primary_completion_date":" 04/02/2019","study_txt":" Completion: 01/19/2021","study_completion_date":" 01/19/2021","last_update_posted":"2021-09-22"}]